Home > Insider Trading > Filing (0001209191-14-072924)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1008848	Acorda Therapeutics Inc	ACOR	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1272354	Ron Cohen	420 Saw Mill River Road Ardsley NY 10502	President And Ceo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-12-01	51,265	$8.14	529,794	No	4	M	Direct
Common Stock	Disposition	2014-12-01	34,394	$35.59	495,400	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2014-12-01	51,265	$0.00	51,265	$8.14

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2015-01-01	No	4	M	Direct

Footnotes

Exercise and sales pursuant to a 10b5-1 plan. Dr. Cohen exercised 51,265 stock options, all of which were due to expire 1/1/2015 unless exercised. Dr. Cohen sold 19,200 of the resultant shares, the proceeds of which are being used to fund the exercise of the options and the resulting tax liability. In addition, Dr. Cohen vested in 30,384 shares of restricted stock of which he sold 15,194 shares, the proceeds of which are being used to fund the resulting tax liability. A record of all of Dr. Cohen's holdings is available in Acorda's SEC filings. Dr. Cohen retains the majority of the equity he has been granted in the Company since founding Acorda in 1995.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $35.27 to $36.27 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The shares subject to these options vested in installments and were fully vested on 3/01/2009.